A5054480372- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiac pacing and defibrillation studies
- Cardiac electrophysiology and arrhythmias
- Venous Thromboembolism Diagnosis and Management
- Coronary Interventions and Diagnostics
- Cardiac Imaging and Diagnostics
- Peripheral Artery Disease Management
- Cardiovascular Syncope and Autonomic Disorders
- Cardiovascular Effects of Exercise
- Central Venous Catheters and Hemodialysis
- Cardiac tumors and thrombi
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular and Diving-Related Complications
- Cardiac Structural Anomalies and Repair
- Cardiac Valve Diseases and Treatments
- MicroRNA in disease regulation
- ECG Monitoring and Analysis
- Tracheal and airway disorders
- Cardiomyopathy and Myosin Studies
- Mesenchymal stem cell research
- Esophageal and GI Pathology
- Electrospun Nanofibers in Biomedical Applications
- Tissue Engineering and Regenerative Medicine
- Cardiovascular Issues in Pregnancy
Asklepios Klinik Altona
2024-2025
University Hospital Schleswig-Holstein
2018-2025
University of Lübeck
2010-2025
German Centre for Cardiovascular Research
2015-2025
University Medical Center Hamburg-Eppendorf
2015-2025
Universität Hamburg
2015-2025
Universitäres Kinderwunschzentrum Lübeck
2021-2025
Asklepios Klinik St. Georg
2015-2024
Helios Kliniken
2024
Helios Hospital Schwerin
2024
The use of second-generation cryoballoon for pulmonary vein isolation in patients with paroxysmal atrial fibrillation has demonstrated encouraging acute and mid-term results. Long-term outcome data are not yet available.Fifty (18 women; mean age, 61±11 years; left diameter, 43±5 mm) (36 50 patients; 72%) or short-standing (<3-month duration) persistent (14 28%) underwent cryoballoon-based isolation. Freeze cycle duration was 240 seconds. After successful isolation, a bonus freeze applied....
Electric left atrial appendage (LAA) isolation (LAAI) may occur during catheter ablation of tachyarrhythmias. Data regarding the risk thromboembolic events and stroke after LAAI are sparse. This study evaluated incidence LAA thrombus formation LAAI.Fifty patients had (age=71 years; female=56%; CHA2DS2-VASc score before =3 [2;3]). were compared with matched comparable baseline characteristics who underwent fibrillation without (n=50). Ablation strategies in group included pulmonary vein 50...
Pulsed field ablation is a novel nonthermal cardiac modality using ultra-rapid electrical pulses to cause cell death by mechanism of irreversible electroporation. Unlike the traditional energy sources, pulsed has demonstrated significant preferentiality myocardial tissue ablation, and thus avoids certain thermally mediated complications. However, its safety effectiveness remain unknown in usual clinical care.MANIFEST-PF (Multi-National Survey on Methods, Efficacy, Safety Post-Approval...
Catheter ablation for ventricular tachycardia (VT) reduces the recurrence of VT in patients with implantable cardioverter-defibrillators (ICDs). The appropriate timing and its effects on mortality heart failure progression remain a matter debate. In life-threatening arrhythmias necessitating ICD implantation, we compared outcomes preventive (undertaken before implantation to prevent shocks VT) deferred after 3 VT. BERLIN study (Preventive Ablation Ventricular Tachycardia Patients With...
Abstract Aims Oesophageal fistula represents a rare but dreadful complication of atrial fibrillation catheter ablation. Data on its incidence, management, and outcome are sparse. Methods results This international multicentre registry investigates the characteristics oesophageal fistulae after treatment by A total 553 729 ablation procedures (radiofrequency: 62.9%, cryoballoon: 36.2%, other modalities: 0.9%) were performed, at 214 centres in 35 countries. In 78 138 patients [0.025%,...
Initial clinical studies of pulsed field ablation (PFA) to treat atrial fibrillation (AF) indicated a >90% durability rate pulmonary vein isolation (PVI). However, these were largely conducted in single centers and involved limited number operators. The electrophysiological findings outcomes patients undergoing repeat after an initial PF for AF are incompletely understood. In the MANIFEST-REDO study, we investigated who underwent due recurrence - or tachycardia (AT) following first-ever PVI...
Pulmonary vein isolation (PVI) for persistent atrial fibrillation is associated with limited success rates and often requires multiple procedures to maintain stable sinus rhythm. In the prospective randomized Alster-Lost-AF trial (Ablation at St. Georg Hospital Long-Standing Persistent Atrial Fibrillation), we sought assess, in patients symptomatic or long-standing fibrillation, outcomes of initial ablative strategies comprising either stand-alone PVI (PVI-only approach) a stepwise approach...
Despite advances in stent technology for vascular interventions, in-stent restenosis (ISR) because of myointimal hyperplasia remains a major complication.We investigated the regulatory role microRNAs hyperplasia/ISR, using humanized animal model which balloon-injured human internal mammary arteries with or without stenting were transplanted into Rowett nude rats, followed by microRNA profiling. miR-21 was only significantly upregulated candidate. In addition, expression increased tissue...
The second-generation cryoballoon delivers effective pulmonary vein isolation (PVI) associated with superior 1-year clinical outcome. However, data on reconduction of previously isolated PV are sparse.A total 421 patients underwent 28-mm cryoballoon-based PVI in 2 centers (St. George's hospital and Harburg hospital, Hamburg, Germany) between June 2012 May 2015. Sixty-six (16%) (39/66, 59% women; mean age, 63±10 years, left atrium diameter, 45±6 mm) a history paroxysmal (40/66, 61%) or...
Background: Cryoballoon-based pulmonary vein isolation (PVI) has emerged as an effective treatment for atrial fibrillation. The most frequent complication during cryoballoon-based PVI is phrenic nerve injury (PNI). However, data on PNI are scarce. Methods: YETI registry a retrospective, multicenter, and multinational evaluating the incidence, characteristics, prognostic factors recovery follow-up of patients with PVI. Experienced electrophysiological centers were invited to participate. All...
Catheter ablation for atrial fibrillation (AF) treatment provides effective and durable pulmonary vein isolation (PVI) is associated with encouraging clinical outcome. A novel CF sensing temperature-controlled radiofrequency (RF) catheter allows very high-power short-duration (vHP-SD, 90 W/4 s) aiming a potentially safer, more faster ablation. We thought to evaluate preliminary safety efficacy of vHP-SD PVI utilizing catheter. The data was compared conventional power-controlled index (AI)...
The very high-power short-duration (vHP-SD) radiofrequency (RF) ablation concept of atrial fibrillation (AF) treatment by pulmonary vein isolation (PVI) aims for safer, more effective, and faster procedures. Utilizing conventional ablation, the 'close protocol' has been verified. Since lesion formation vHP-SD creates wider but shallower lesions we adapted close protocol to an individualized tighter 'very-close 3-4 mm inter-lesion distance (ILD) at anterior 5-6 posterior aspect left atrium...
Abstract Aims Simplified ablation technologies for pulmonary vein isolation (PVI) are increasingly performed worldwide. One of the most common complications following PVI vascular access-related complications. Lately, venous closure systems (VCSs) were introduced into clinical practice, aiming to reduce time bed rest, increase patients’ comfort, and The aim present study is compare safety efficacy using a VCS achieve haemostasis single-shot actual standard care [figure-of-eight suture manual...
Studies on the use of second-generation 28 mm cryoballoon (CB) for treatment atrial fibrillation (AF) have reported superior 1-year clinical outcome. Customarily, a bonus freeze cycle is applied after pulmonary vein isolation (PVI). The purpose present study was to assess outcome following PVI foregoing cycle. Patients with drug-refractory paroxysmal AF (PAF) or persistent underwent using CB. duration set at 240 s. No applied. Clinical follow-up (FU) included 12-lead ECGs and 24h-Holter 3,...
The purpose of this study was to determine efficacy pulmonary vein isolation (PVI) using the 28 mm cryoballoon (CB) in patients with persistent atrial fibrillation (AF). Superior acute and 1-year outcome has been demonstrated following PVI, second-generation CB paroxysmal AF. Data on AF are sparse.Forty-nine (20 female, mean age 63 ± 10 years, left diameter 46 5 mm) [median duration since first diagnosis: 48 (20:192) months] underwent CB-based PVI. freeze cycle set at 240 s. After successful...
The prevalence of atrial fibrillation (AF) increases with age. Catheter ablation is an established treatment option for patients symptomatic AF. We sought to determine the safety and long-term clinical efficacy AF in ≥75 years.Patients years symptomatic, drug-refractory were included study. Circumferential pulmonary vein isolation (PVI) was performed all patients, extended complex fractionated electrograms, and/or linear lesions PVI non-responders. Retrospective follow-up (FU) based on...
Second-generation cryoballoon (CB2)-based pulmonary vein isolation (PVI) has demonstrated encouraging clinical results in the treatment of paroxysmal (PAF) and persistent atrial fibrillation (PersAF). However, CB2 features a maximal diameter 28 mm, its adaptability to anatomic variations veins (PVs) might be challenging.The purpose this study was assess acute efficacy, safety, long-term CB2-based PVI patients with left common (LCPV).Six hundred seventy consecutive underwent 3...
Circumferential pulmonary vein isolation (CPVI) is increasingly performed for the treatment of symptomatic drug-refractory paroxysmal atrial fibrillation. Long-term data >10 years after CPVI are sparse. We investigated long-term clinical outcome and progression fibrillation double-lasso 3-dimensional electroanatomical mapping-guided CPVI.From 2003 to 2004, 161 patients (mean age: 60±10 years) with were prospectively enrolled underwent CPVI. Right-sided left-sided continuous circular lesions...
Pulmonary vein isolation (PVI) either by balloon devices or radiofrequency forms the cornerstone of invasive atrial fibrillation (AF) treatment. Although equally effective cryoballoon (CB)-based PVI offers shorter procedure duration and a better safety profile. Beside worldwide established Arctic Front Advance system, novel CB device, POLARx, was recently introduced. This incorporates unique features, which may translate into improved efficacy safety. However, multicentre assessment...
Pulsed field ablation (PFA) is a non-thermal energy source with promising safety and efficacy advantages. We aimed to develop convenient, safe, effective fast method of pulmonary vein isolation (PVI) utilizing penta-spline PFA catheter via single femoral venous closure system.
Abstract Introduction Atrio‐esophageal fistula after esophageal thermal injury (ETI) is one of the most devastating complications available energy sources for atrial fibrillation (AF) ablation. Pulsed field ablation (PFA) uses electroporation as a new source catheter with promising periprocedural safety advantages over existing methods due to its unique myocardial tissue sensitivity. In preclinical animal studies, dose‐dependent temperature rise has been reported. TESO‐PFA registry...
Background:Pulmonary vein isolation (PVI) using the 2nd-generation cryoballoon (CB2) for treatment of atrial fibrillation (AF) has demonstrated encouraging acute and mid-term results. However, follow-up data on outcomes beyond 1 year are sparse. We investigated 3-year outcome after PVI CB2.
Second-generation cryoballoon based pulmonary vein isolation has demonstrated encouraging acute and mid-term clinical outcome. Customarily, a bonus-freeze is applied after successful isolation. To compare the long-term outcome safety profile of no protocol. A total 120 consecutive patients with paroxysmal [95/120 (79 %)] or persistent atrial fibrillation [25/120 (21 underwent CB2-based PVI. Freeze-cycle duration was 240 s. In first 60 PVI (group 1), while in following omitted 2). Procedure...